Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Sanofi (SNY) and partner Regeneron (REGN) announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United States. The approved indication is as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype. With this approval, Dupixent became the first biologic treatment approved for COPD in the United States. Dupixent was approved for treating COPD with raised blood eosi ...